These patients were considered to be less likely to experience ILD even when treated with panitumumab (the incidence of ILD was 0.66 % [6/914] in patients who received panitumumab among patients who had received the other anti-EGFR monoclonal antibody and had not experienced ILD). The gene discussed is EGFR; the disease is interstitial lung disease.